What is KRYS's health score?

Krystal Biotech, Inc. (KRYS) has a TradeApes health score of 59 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is KRYS's estimated fair value?

Based on our 5-year discounted cash flow model, Krystal Biotech, Inc.'s estimated fair value is $58.27 per share, representing a -80.6% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is KRYS undervalued or overvalued?

Our model currently rates KRYS as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for KRYS... Refresh in a moment for the full analysis.

Krystal Biotech, Inc. (KRYS)

Healthcare Overvalued low mixed

$301.0

Updated: 2026-06-06

TradeApes Score

Financial Strength

75 Strong

Operating Trend

55 Mixed

Relative Value

48 Mixed

Capital Allocation

40 Weak

Risk

80 Strong

Est. Fair Value $58.27

DCF Upside -80.6%

Sector Rank #144 of 6717

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− High P/E — 25–45×, growth premium already priced in

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.